Pharmaceutical companies in Europe continue to drive transparency

Over the next 10 days, pharmaceutical companies will disclose details of collaborations with health professionals (HCPs) and healthcare organizations (HCOs) across Europe.

The figures, which will be available online, underline industry’s continued investment in European healthcare, enabling the development of new medicines through sharing best clinical practice, exchanging information on how new medicines fit into the patient pathway and shaping the future of clinical research, according to the trade group European Federation of Pharmaceutical Industries and Associations (EFPIA).

Nathalie Moll, director general of the EFPIA, said: “Discovering, developing and delivering new medicines to patients is challenging. It often requires collaboration and dialogue, with patients, with healthcare professionals and with healthcare organizations. The transparency of these relationships is vital to build understanding and ensure confidence. That is why EFPIA and its members have committed to disclosing annually transfers of value to health professionals and healthcare organisations.”